Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
DVx Inc. (3079.T)
Tokyo, JP
DVx Inc., a Japanese company founded in 1986 and headquartered in Tokyo, specializes in the import and export of medical devices and their accompanying peripheral equipment within Japan. The firm offers a diverse portfolio of products, including those addressing arrhythmia, such as cardiac pacemakers, implantable cardioverter defibrillators, and various electrode and ablation catheters. It also provides ischemia-related solutions, notably excimer laser systems. A significant portion of its offerings includes specialized equipment designed to minimize scatter radiation exposure for medical personnel during fluoroscopy procedures, featuring products like RADPAD (for general protection), RADNEK (for thyroid protection), and RADCAP (for head protection). Additionally, DVx supplies resolution/resolution SD devices and wonder belt products. Beyond sales and distribution, the company is actively involved in the full spectrum of medical device operations, encompassing research, development, manufacturing, repair, and leasing. DVx Inc. further provides general consulting and services related to medical and medical device industries, alongside engaging in medical publishing and market research activities.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.40% | -5.57% | -18.37% | -14.46% | -15.97% | +12.36% | +1.21% | +2.25% | -7.92% | +407.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+11.3% ★ Q1'26: +4.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-45.2% Q1'26: -40.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-2.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+0.5% Q1'26: +0.8% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+4.8% ★ Q1'26: +10.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.3% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.02× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
|---|---|---|---|---|---|
| Revenue |
28.65B
est: 27.60B (+3.8%)
|
31.37B
est: 31.05B (+1.0%)
|
35.27B
est: 35.75B (-1.4%)
|
38.28B
est: 37.99B (+0.8%)
|
40.38B
est: 40.86B (-1.2%)
|
| EBITDA |
1.54B
est: 785.22M (+96.4%)
|
1.62B
est: 883.37M (+83.3%)
|
1.65B
est: 1.02B (+62.4%)
|
1.51B
est: 1.08B (+39.6%)
|
1.46B
est: 1.16B (+25.4%)
|
| EBIT |
1.43B
est: 527.94M (+171.1%)
|
1.49B
est: 593.93M (+151.3%)
|
1.51B
est: 683.84M (+120.9%)
|
1.33B
est: 726.68M (+83.7%)
|
1.24B
est: 781.58M (+58.3%)
|
| Net Income |
919.95M
est: 779.44M (+18.0%)
|
1.29B
est: 1.02B (+26.4%)
|
1.03B
est: 974.04M (+5.3%)
|
856.13M
est: 1.08B (-20.5%)
|
974.18M
est: 1.12B (-13.2%)
|
| SGA |
3.34B
est: 2.43B (+37.6%)
|
3.37B
est: 2.73B (+23.3%)
|
3.65B
est: 3.15B (+16.0%)
|
3.83B
est: 3.34B (+14.6%)
|
4.07B
est: 3.60B (+13.1%)
|
| EPS |
81.57
est: 74.50 (+9.5%)
|
114.36
est: 97.50 (+17.3%)
|
90.98
est: 93.10 (-2.3%)
|
75.92
est: 102.90 (-26.2%)
|
88.46
est: 107.30 (-17.6%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideki Nakai | Executive Officer | — | — |
| Hiroshi Shibasaki | President, Chief Executive Officer & Director | — | male |
| Masaru Kasono | Vascular Sales Department Manager & Executive Officer | — | — |
| Satoshi Miyamoto | Executive Officer & Director | — | male |
| Satoshi Suwa | Executive Officer & Director | — | — |
| Takeshi Hatano | Executive Officer, GM of Central Japan Third Sales Department & Director | — | — |
| Takeshi Nagata | Executive Officer | — | — |
| Takeshi Takada | Executive Officer | — | male |
| Tatsuya Kimura | Executive Officer | — | — |
| Yusai Furukawa | Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3079.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
